Blog RSS Blog.

Ethics, refugees, and the President’s Executive Order

02/21/2017

by Nancy Kass, ScD
There are different political philosophies about the responsibilities of states regarding whether to accept refugees. While there is a political philosophy that might be called Nationalist in perspective that says, essentially, “Not my Problem,” the predominant philosophy globally is different. That philosophy says that the refugee crisis is a global problem, people are in need, and we have the capacity to help. The reasoning behind this latter view recognizes that the benefit to others in accepting refugees is a matter of life and death, and the sacrifice to countries who accept them is, in the long run, minimal.…

Btn Rss Bioethics News.

02/23/2017
How Silicon Valley Is Trying to Hack Its Way Into a Longer Life Time

Rather than wait years for treatments to be approved by federal officials, many of them are testing ways to modify human biology that fall somewhere on the spectrum between science and entrepreneurialism. It’s called biohacking, and it’s one of the biggest things happening in the Bay Area.

02/22/2017
Artificial intelligence grows a nose Science

Now, 22 teams of computer scientists have unveiled a set of algorithms able to predict the odor of different molecules based on their chemical structure. It remains to be seen how broadly useful such programs will be, but one hope is that such algorithms may help fragrancemakers and food producers design new odorants with precisely tailored scents.

02/21/2017
Harvard and M.I.T. Scientists Win Gene-Editing Patent Fight The New York Times

The Broad Institute in Cambridge, Mass., will retain potentially lucrative rights to a powerful gene-editing technique that could lead to major advances in medicine and agriculture, the federal Patent and Trademark Office ruled on Wednesday.

02/17/2017
An old drug gets a new price to fight a rare disease: $89,000 a year Washington Post

An old steroid treatment, long available outside the United States, received approval this week for a rare disease that afflicts about 15,000 Americans. Though not previously approved in the United States, the drug, deflazacort, has for years been available to patients suffering from the devastating and fatal disease Duchenne muscular dystrophy; families can import it from abroad for about $1,200 per year on average. The new list price for the drug? $89,000 a year.